Faculty Collaboration Database

Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys 2004 Jul 01;59(3):706-12

Date

06/09/2004

Pubmed ID

15183474

DOI

10.1016/j.ijrobp.2003.12.038

Scopus ID

2-s2.0-2942567735 (requires institutional sign-in at Scopus site)   97 Citations

Abstract

PURPOSE: The aim was to evaluate pretreatment lymph node size, irradiation dose, and failure patterns.

METHODS: Pretreatment PET and CT were performed in 208 patients. Lymph nodes were scored as either positive or negative by PET and lymph node size was measured by CT. Lymph node irradiation dose and sites of failure were recorded.

RESULTS: The mean pelvic lymph node doses were: PET negative nodes, < or =1 cm, 66.8 Gy, and 0/76 failures; PET positive nodes, < or =1 cm, 66.8 Gy, and 3/89 failures; 1.1-< or =2 cm, 66.9 Gy, and 0/21 failures; 2.1-< or =3 cm, 69.4 Gy, and 2/15 failures; and 3.1 to < or =4 cm, 74.1 Gy, and 0/5 failures. The mean paraaortic lymph node dose was 43.3 Gy and there were no paraaortic failures for 24 patients with PET positive < or =1 cm nodes, 0/5 failures for 1.1 to < or =2 cm, and 0/4 failures for 2.1 to < or =3 cm. The most common site of failure was distant metastases.

CONCLUSIONS: The irradiation doses given in this study were adequate to control most lymph node metastases. Positive lymph nodes of any size at diagnosis were the most significant predictor for developing distant metastases.

Author List

Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I

Author

Janet Sue Rader MD Chair, Professor in the Obstetrics and Gynecology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Aged, 80 and over
Brachytherapy
Female
Fluorodeoxyglucose F18
Humans
Lymph Nodes
Lymphatic Metastasis
Middle Aged
Radiopharmaceuticals
Radiotherapy Dosage
Retrospective Studies
Tomography, Emission-Computed
Tomography, X-Ray Computed
Uterine Cervical Neoplasms